This company has been marked as potentially delisted and may not be actively trading. Blueprint Medicines (BPMC) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for BPMC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMC Analyst Ratings Over TimeTypeCurrent Forecast9/29/24 to 9/29/251 Month Ago8/30/24 to 8/30/253 Months Ago7/1/24 to 7/1/251 Year Ago9/30/23 to 9/29/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)2 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)4 Buy rating(s)11 Buy rating(s)Hold16 Hold rating(s)16 Hold rating(s)17 Hold rating(s)5 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$130.00$130.00$128.06$120.00Forecasted Upside0.42% Upside0.42% Upside-0.22% Downside29.66% UpsideConsensus RatingHoldHoldHoldModerate Buy BPMC Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BPMC Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Blueprint Medicines Stock vs. The CompetitionTypeBlueprint MedicinesMedical CompaniesS&P 500Consensus Rating Score 2.11 2.78 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside0.42% Upside2,562.73% Upside11.53% UpsideNews Sentiment RatingNeutral NewsSee Recent BPMC NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails6/17/2025Wells Fargo & Company3 of 5 starsDerek Archila Not RatedDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00+0.66%6/5/2025Morgan Stanley3 of 5 starsJudah Frommer Not RatedBoost TargetEqual Weight$102.00 ➝ $129.00+0.79%6/5/2025UBS Group4 of 5 starsDavid Dai Not RatedBoost TargetNeutral$88.00 ➝ $129.00+0.70%6/4/2025CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid LebowitzSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00+1.10%6/3/2025GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingM. SchmidtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingSet Target$132.00+3.14%6/3/2025TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingM. FrahmSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingR. BenjaminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025JMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReni BenjaminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform6/3/2025Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingA. ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSudan LoganathanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$150.00 ➝ $135.00+5.64% Get the Latest News and Ratings for BPMC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. 6/2/2025CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeHold6/2/2025JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian ChengSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$130.00 ➝ $129.00+1.01%6/2/2025ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingL. ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeStrong-Buy ➝ Sector Perform$135.00+5.71%6/2/2025WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDavid NierengartenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$128.00 ➝ $129.00+27.53%6/2/2025Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAmi FadiaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold$130.00+28.52%5/2/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew FeinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$135.00 ➝ $135.00+36.02%3/17/2025Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael YeeSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$135.00+50.70%1/27/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingChristopher RaymondSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$109.00 ➝ $119.00+2.06%8/2/2024Baird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingC. KusySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeStrong-Buy8/2/2024Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$112.00 ➝ $127.00+30.24%7/29/2024BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetEqual Weight$75.00 ➝ $105.00-4.93%7/8/2024OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOutperform$114.00 ➝ $125.00+11.91%5/6/2024Leerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingA. BerensSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeUnderperform ➝ Market Perform5/6/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$121.00 ➝ $168.00+57.78%5/6/2024Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeUnderperform ➝ Market Perform$50.00 ➝ $97.00-9.51%4/26/2024Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$120.00 ➝ $130.00+40.00%12/22/2023Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetStrong-Buy$85.00 ➝ $100.00+16.37%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:29 PM ET. BPMC Forecast - Frequently Asked Questions What is Blueprint Medicines' forecast for 2025? According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Blueprint Medicines is $130.00, with a high forecast of $135.00 and a low forecast of $119.00. Should I buy or sell Blueprint Medicines stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 16 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BPMC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BPMC, but not buy additional shares or sell existing shares. Does Blueprint Medicines's stock price have much upside? According to analysts, Blueprint Medicines's stock has a predicted upside of 0.42% based on their 12-month stock forecasts. Do Wall Street analysts like Blueprint Medicines more than its competitors? Analysts like Blueprint Medicines less than other "medical" companies. The consensus rating for Blueprint Medicines is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BPMC compares to other companies. Stock Forecasts and Research Tools Related Companies Insmed Stock Forecast BioNTech Stock Forecast Teva Pharmaceutical Industries Stock Forecast Genmab A/S Stock Forecast Summit Therapeutics Stock Forecast Dr. Reddy's Laboratories Stock Forecast Ascendis Pharma A/S Stock Forecast Viatris Stock Forecast Roivant Sciences Stock Forecast QIAGEN Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:BPMC) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
